Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 9689 - 9696 of 12128 results
Supreme Court to Hear Argument on March 31 Whether to Overrule Brulotte v. Thys, Co.
March 25, 2015| Blog| Viewpoint
The FCC and the Uncertain Future of Privacy Oversight for Internet Service Providers
March 25, 2015| Blog| Viewpoint
USITC Declines to Institute Investigation of Induced Patent Infringement as Unfair Method of Competition or Unfair Acts
March 24, 2015| Blog| Viewpoint
Mintz Attorneys to Discuss 340B Program, Overpayments and Stark Self-Disclosures at AHLA Medicare & Medicaid Institute
March 24, 2015| Blog| Viewpoint
March 23, 2015 Marks the 5th Anniversary of the Affordable Care Act
March 23, 2015| Blog| Viewpoint
More “Broken Windows”: SEC Charges Schedule 13D Filers with Disclosure Violations for Failing to Update Ownership Reports
March 23, 2015| Blog| Viewpoint
Tips for Effectively Organizing PTAB Appeals Brief - Claim Grouping
March 23, 2015| Blog| Viewpoint
$12.6 Million Sandoz ASP Reporting Settlement Raises More Questions Than It Answers
March 23, 2015| Blog| Viewpoint
News & Press Releases
Mintz Advises on LB Pharmaceuticals’ $285 Million Initial Public Offering
September 12, 2025
Mintz advised the underwriters in connection with a $285 million initial public offering by LB Pharmaceuticals Inc of 19,000,000 shares of common stock at an initial public offering price of $15.00 per share. The aggregate gross proceeds to LB Pharmaceuticals from this offering were approximately $285 million before deducting underwriting discounts and commissions and other offering expenses. In addition, LB Pharmaceuticals granted the underwriters a 30-day option to purchase up to an additional 2,850,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares began trading on the Nasdaq Global Market on September 11, 2025 under the ticker symbol “LBRX.”
Mintz Advises the Placement Agents in CAMP4’s up to $100 Million Private Placement
September 12, 2025
Mintz advised the placement agents in connection with CAMP4's up to $100 million private placement. The private placement included upfront gross proceeds of $50 million in exchange for common stock (and pre-funded warrants in lieu of common stock for certain investors). In addition, CAMP4 will be eligible to receive up to an additional $50 million in gross proceeds in exchange for common stock (and pre-funded warrants for certain investors), subject to achieving pre-specified milestones, including receipt of regulatory clearance to initiate a Phase 1/2 clinical trial in SYNGAP patients with its development candidate, CMP-SYNGAP-01.
Mintz Advises Premier Wealth Advisor Breed’s Hill Capital on Acquisition by Corient
September 12, 2025
Mintz represented Breed’s Hill Capital, a multi-family office overseeing approximately $3.5 billion in assets, in its acquisition by Corient, one of the nation’s leading wealth management firms. The transaction enhances Corient’s footprint in New England and advances its ability to deliver personalized fiduciary wealth management services across the region.
Events
Podcasts
Mintz On Air: Practical Policies – Disparage Me Not
August 26, 2025| Podcast|
Mintz On Air: Practical Policies - Investigations Unscripted
August 12, 2025| Podcast|
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|